Portugália is expanding in Macau, targeting Hong Kong, and returning to Hengqin. CEO Francisco Carvalho Martins sees Macau as ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...

Zai Lab Limited today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment ...

BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.

WHARF REIC Annual Underlying NP Hikes 2% to $6.14B; 2nd Interim DPS $0.6 ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

As global markets face challenges such as trade policy uncertainties and inflation concerns, Asian tech stocks have been drawing attention for their potential to navigate these turbulent waters. In ...

Tu Haiming of China’s top advisory body issues call at meeting amid Beijing’s most important annual political gathering, ...